RespireRx Pharmaceuticals Inc. RSPI
0.00 USD 0.00 (+0.00%)
At closeDec 15, 2025, 4:00 PM EST
0.0014 Day range 0.0018
0.0001 52-week range 0.0027
- YTD
- 0.00%
- 1 year
- +125.00%
- Market cap
- 657.75K
- EPS (ttm)
- -0.02
- P/E ratio
- -0.09
- YTD return
- 0.00%
- 1-year return
- +125.00%
- Volume
- 200
- Avg volume
- 30.10K
- Open
- 0.0014
- Previous close
- 0.0018
- Day's range
- 0.0014 – 0.0018
- 52-week range
- 0.0001 – 0.0027
- Earnings date
- Apr 17, 2023
No chart data for this range yet.
Next earnings
Apr 17, 2023
Expected Apr 17, 2023. Consensus EPS estimate 0.00.
Financials — quick view
RSPI Revenue — quarterly 0
RSPI Net income — quarterly -860.16K
RSPI EPS — quarterly -0.01
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 17, 2023 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 21, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
| May 22, 2023 | Mar 1, 2023 | 0.00 | -0.01 | — | — |
| Apr 17, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 17, 2022 | Sep 1, 2022 | 0.00 | -0.01 | — | — |
| Aug 22, 2022 | Jun 1, 2022 | 0.00 | -0.01 | — | — |
News
Reviewing Cortex Pharmaceuticals (OTCMKTS:RSPI) & Stoke Therapeutics (NASDAQ:STOK) 
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties 
RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement 
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury 
RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury 
RespireRx's key asset moves to next stage of NIH initiative 
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine 
RespireRx Pharmaceuticals strengthens board, adding new director 
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors 
RespireRX Pharmaceuticals reports ‘highly encouraging' case study results for KRM-II-81
Your note
Sign in to keep a note on RSPI — it syncs with the Stock Master app.